Effect of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease
Phase 3
- Conditions
- Type 2 diabetes with PAD
- Registration Number
- JPRN-jRCT2031200141
- Lead Sponsor
- Higo Yasumoto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
Male or female, age above or equal to 18 years at the time of informed consent (above or equal to 20 years for Japan)
-Diagnosed with type 2 diabetes
-Symptomatic PAD with intermittent claudication in Fontaine stage IIa
Exclusion Criteria
-Treatment with GLP-1receptor agonist or DPP4 inhibitor
-Walking ability limited by condition other than PAD
-Planned orthopaedic surgery or other major surgery
-Vascular revascularisation procedure 180 days prior to screening or planned
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment ratio of the median ratio to baseline at week 52 in maximum walking distance
- Secondary Outcome Measures
Name Time Method